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Background: Most patients with cystic fibrosis (CF) have a DF508 mutation resulting in abnormal retention
of mutant gene protein (DF508-CFTR) within the cell. This study was undertaken to investigate DF508-CFTR
trafficking in native cells from patients with CF with the aim of discovering pharmacological agents that can
move DF508-CFTR to its correct location in the apical cell membrane.
Method: Nasal epithelial cells were obtained by brushing from individuals with CF. CFTR location was
determined using immunofluorescence and confocal imaging in untreated cells and cells treated with
sildenafil. The effect of sildenafil treatment on CFTR chloride transport function was measured in CF15 cells
using an iodide efflux assay.
Results: In most untreated CF cells DF508-CFTR was mislocalised within the cell at a site close to the
nucleus. Exposure of cells to sildenafil (2 hours at 37 C˚) resulted in recruitment of DF508-CFTR to the
apical membrane and the appearance of chloride transport activity. Sildenafil also increased DF508-CFTR
trafficking in cells from individuals with CF with a single copy DF508 (DF508/4016ins) or with a newly
described CF trafficking mutation (R1283M).
Conclusions: The findings provide proof of principle for sildenafil as a DF508-CFTR trafficking drug and
give encouragement for future testing of sildenafil and related PDE5 inhibitors in patients with CF.
C
ystic fibrosis (CF) is caused by mutations in the CF
gene protein, the cystic fibrosis transmembrane con-
ductance regulator (CFTR).1 By far the most common
mutation is DF508, present on 70–80% of chromosomes
worldwide. Wild type CFTR resides at the apical membrane of
epithelial cells where it acts as a cyclic AMP-dependent Cl2
channel1 and regulates other ion channels2 and protein
secretion.3 Defective trafficking of DF508-CFTR leads to
abnormal retention of mutant protein within the cell and
consequent loss of CFTR function.1 The reported degree of
mislocalisation of DF508-CFTR in native epithelial cells varies
between different tissues and types of preparation.4–7 More
recently we and others have developed a technique to study
the location of CFTR in freshly isolated native airway
epithelial cells from patients with CF which allows quantita-
tion of the percentage of cells with a defined CFTR location.8 9
We have shown a marked mislocalisation of DF508-CFTR
which was corrected by the CFTR activating benzo[c]quino-
lizinium compounds.8 Thus, although our studies and those
of others suggest that at least some DF508-CFTR traffics to
the apical membrane in native CF cells,7–9 the finding that the
majority of DF508-CFTR is mislocalised8 emphasises that
moving DF508-CFTR to the apical membrane is necessary for
developing a drug treatment targeted at CFTR rescue.
Arising from our earlier studies showing correction of
antibody inhibited CFTR function by cyclic nucleotide
phosphodiesterase (PDE) inhibitors,10 we now show that
the PDE5 inhibitor sildenafil (Viagra) increases DF508-CFTR
trafficking. Since this is a drug in clinical use that causes
rapid movement of DF508-CFTR from within the cell to the
apical membrane, the results represent a major step forward
in the development of a treatment that addresses the basic
cellular abnormality for the majority of patients with CF.
METHODS
Patients and cell sampling
Airway epithelial cells were obtained by nasal brushing from
three non-CF individuals (age 9–22 years) and from six CF
individuals (age 6 months to 16 years) undergoing flexible
bronchoscopy under sedation as previously described.8 The
CF individuals had the following genotypes: four DF508/
DF508, one DF508/4016ins, and one R1283M/E60X. The
study was approved by the local ethics committee of Bro Taf
Health Authority.
CFTR localisation in nasal epithelial cells
Immediately following nasal brushing, the brushes were
placed in DMEM/F12 medium and the attached cells
incubated in the presence or absence of sildenafil (150 mM)
for 2 hours at 37 C˚. Cells were then fixed and CFTR localised
by immunofluorescence as previously described.8 Briefly,
after incubation, cells were smeared gently onto ‘‘Snowcoat
X-tra’’ microslides (Surgipath), left to air dry, fixed for
5 minutes at 220 C˚ in 5% acetic acid in ethanol, washed in
phosphate buffered saline (PBS) containing (in mM): 137
NaCl, 2.7 KCl, 4.3 Na2HPO4, 1.4 KH2PO4, pH 7.4 and stored at
220 C˚. Following treatment with blocking reagent (normal
rabbit serum 1:20), cells were incubated with primary
antibody overnight at 4 C˚, washed three times, and incubated
with FITC conjugated secondary antibody (1:100) for
30 minutes at room temperature. The CFTR antibody used
was our well characterised anti-CFTR antibody MPCT1
(affinity purified C-terminal; 1:100).8 Slides were then
mounted in Fluorosave Reagent (Calbiochem, La Jolla,
CA, USA) and fluorescence was detected using confocal
laser scanning microscopy on a Leitz DMRBE microscope
(Leica, Germany) fitted with a TCS4D scanner (Leica,
Germany).
Measurement of chloride transport activity in CF15
cells
The SV40 transformed nasal epithelial cell line JME/CF15
from a patient with CF (DF508/DF508)11 was cultured in
DMEM/F12 supplemented with adenine (180 mM), insulin
(5 mg/ml), transferrin (5 mg/ml), hydrocortisone (1.1 mM),
tri-iodothyronine (2 nM), epinephrine (5.5 mM), epidermal
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growth factor (1.64 nM) and 10% FCS. Chloride channel
activity was assayed by measuring the rate of iodide (125I)
efflux.8 12 CF15 cells were incubated for 2 hours at 37 C˚ in the
presence or absence of either sildenafil or MPB-91 (250 mM).
Cells were then washed with efflux buffer containing (in
mM): 137 NaCl, 4.4 KCl, 0.3 KH2PO4, 0.3 NaH2PO4, 4.2
NaHCO3, 1.3 CaCl2, 0.5 MgCl2, 0.4 MgSO4, 5.6 glucose and 10
HEPES, pH 7.5 and incubated in efflux buffer containing
1 mM KI and 1 mCi Na125I /ml (NEN, Boston, MA, USA) for
2 hours at 37 C˚. Cells were then washed with efflux buffer.
After 1 minute the buffer was removed and quickly replaced
by 300 ml of the same buffer. The first four aliquots were used
to establish a stable baseline in efflux buffer alone. Efflux
buffer containing forskolin (10 mM) and genistein (30 mM)
to stimulate CFTR activity was used for the remaining
aliquots. At the end of the incubation the buffer was
recovered and cells solubilised in 1 ml 1 N NaOH. The
radioactivity was determined using a gamma counter (Cobra
II, Packard Bell).
Analysis of data
For CFTR localisation up to 140 cells for each condition were
examined, categorised as having a distinct CFTR location of
either near nucleus or apical, and expressed as a percentage
of all cells counted. Only ciliated tall columnar epithelial cells
were counted as these can be readily differentiated from non-
ciliated columnar epithelial cells and basal cells, even when
DF508-CFTR is localised close to the nucleus.
For CFTR chloride transport activity the fraction of initial
intracellular 125I lost during each time point was determined
and time dependent rates (k) of 125I efflux were calculated
from ln (125It1/
125It2)/ (t1 2 t2) where
125It is the intracellular
125I at time t, and t1 and t2 are successive time points.
8 12
Curves were constructed by plotting k versus time. Relative
rates were calculated and correspond to kpeak 2 kbasal (per
minute). Concentration-response curves were constructed by
plotting the percentage activation as a function of the
concentration of sildenafil (100% corresponds to the max-
imum relative rate obtained at the highest concentration, i.e.
1.5 mM). Differences between treated and untreated cells
were examined using the Student’s t test and p values of
,0.05 were considered significant.
RESULTS
Mislocalisation of DF508-CFTR in CF nasal cells
As in our previous studies,8 nasal epithelial cells obtained
by brushing were polarised with cilia visible at the apical
end of the cell that continued to beat for the 2 hour
incubation before fixation. The nasal cells expressed cyto-
keratins typical of epithelial cells throughout the cell. In cells
from non-CF individuals, wild type CFTR was located at the
apical end of the cell (fig 1A). In untreated cells from DF508/
DF508 CF individuals and from a CF individual with the
genotype DF508/4016ins, 60–70% of cells showed a near
nuclear location of DF508-CFTR with only 10% having
DF508-CFTR present at the apical membrane (fig 1B and
F). This is in agreement with our previous data on the
location of CFTR in wild type, DF508/DF508 and DF508/
G551D cells.8
Actions of sildenafil on DF508-CFTR location
In DF508/DF508 cells treated with sildenafil (150 mM for 2 h
at 37 C˚), a marked change in DF508-CFTR location was
observed (fig 1C and F) with a significant decrease (p,0.05)
in the percentage of cells having a near nuclear location and a
significant increase (from 10% to 32%, p,0.05) in cells
having DF508-CFTR at the apical membrane. CFTR was
also relocated in cells with a single copy DF508 genotype
(DF508/4016ins) following sildenafil treatment (fig 1F).
The data indicate that CFTR trafficking drugs such as
sildenafil will be potentially useful in all CF patients carrying
Figure 1 Immunofluorescent images of non-CF and CF nasal epithelial cells showing that sildenafil corrects abnormal mutant CFTR location in CF cells.
Cells were incubated for 2 hours at 37 C˚ without sildenafil (A, B, D) or with 150 mM sildenafil (C, E). Images show CFTR immunofluorescence in green
with the nucleus counterstained with propidium iodide in red. The results are representative of cells from (A) three non-CF individuals, (B, C) four
DF508/DF508 CF individuals, and (D, E) one R1283M/E60X individual. They show that both DF508- and R1283M- CFTR are predominantly
restricted within the cell to a distinct location adjacent to the nucleus (near nucleus) in untreated cells (B, D) whereas, after sildenafil treatment, many
cells have an apical location of CFTR (C, E). (F) Cells were examined (up to 140 cells for each condition) and categorised as having a distinct CFTR
location of either near nucleus or apical. The remainder of both untreated and treated cells showed a more even distribution of CFTR throughout the cell.
Data are mean (SD). *p,0.05 for difference from no treatment.
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a DF508 mutation. Although the concentration of sildenafil
effective in increasing DF508-CFTR trafficking is higher
than might be achieved in plasma (1 mM) following a single
oral dose (100 mg) of Viagra (data from Pfizer: www.
ViagraH.com), nevertheless the data show proof of prin-
ciple for investigating this relatively safe class of compounds
for use in CF. Furthermore, the effect of sildenafil was
selective in that the distinct locations of endoplasmic
reticulum (p115), Golgi (GM130), and 20S proteasome
proteins were not altered with sildenafil treatment (data
not shown) and sildenafil (150 mM, 2 hours) had no effect
on wild type CFTR location (fig 1A, F) in cells from non-CF
individuals.
A new CF trafficking mutation
Cells from a CF individual heterozygous for a rare mis-
sense mutation, R1283M,13 and a stop mutation, E60X,
were also examined (fig 1D–F). As for DF508 expressing
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Figure 2 Correction of the chloride channel activity of CFTR in CF15 human airway epithelial cells by sildenafil. Cells were incubated for 2 hours at
37 C˚ with or without drug and then CFTR Cl2 channel activity measured by iodide efflux as described in the Methods section. All data in (A)–(F) are
mean (SE) for four separate experiments. (A), (C) and (E) show representative traces from single assays. The presence of forskolin (10 mM) and
genistein (30 mM) is indicated by the horizontal bar. (B), (D) and (F) show mean (SE) data for each experimental condition as indicated. (A) %, no
drug; m, sildenafil (1 mM); &, MPB-91 (250 mM). (B) ***p,0.001 for difference from untreated cells; NS, no significant difference. (C) and (D)
Concentration dependence of the effect of sildenafil treatment (2 hours at 37 C˚). (C) &, 300 mM; m, 500 mM; ., 1 mM; X, 1.1 mM; $, 1.3 mM;
%, 1.5 mM sildenafil. (D) Concentration-response curve showing % activation at each sildenafil concentration. (E) and (F) Effect of chloride channel
inhibitors on iodide efflux stimulated by forskolin (10 mM) and genistein (30 mM) from cells treated with sildenafil (1 mM) for 2 hours at 37 C˚.
(E)%, basal;&, no blocker; m, +100 nM calixarene; ., + 500 mM DIDS;X, + 100 mM glibenclamide;$, + 500 mM DPC. (F) Histograms showing
the relative rate (kpeak 2 kbasal) for the experimental conditions indicated below each bar. ***p,0.001 for difference from cells stimulated by forskolin
and genistein (fsk+gst) without the inhibitor; NS, no significant difference.
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cells, the results (fig 1D, F) showed severe mislocalisation
of CFTR with the majority of cells having mutant
CFTR within the cell at a site close to the nucleus (near
nuclear location). The defective location of this mutant
CFTR was also markedly corrected by sildenafil (fig 1E, F)
with the majority of treated cells showing an apical
CFTR location. This is the first description of R1283M as
a trafficking mutation and sildenafil was effective in
correcting the defect. The results indicate that trafficking
mutations in both the first and second nucleotide bind-
ing domains (NBD1 and NBD2) of CFTR are targets for
sildenafil.
Effect of sildenafil on CFTR chloride transport activity
in CF15 cells
The human airway epithelial CF cell line CF15 was used as a
model to study CFTR dependent chloride transport.11 In
untreated CF15 cells there was no stimulation of 125I efflux
in response to the CFTR agonists forskolin and genistein
(fig 2A) consistent with its DF508/DF508 CF origin.11
However, when cells were treated for 2 hours at 37 C˚ with
sildenafil a significant stimulation by forskolin and genistein
was recovered (fig 2A and B). The effect of sildenafil was
similar to that of the potent trafficking drug MPB-91,8
although of lower magnitude. The concentration depen-
dence of the effect of sildenafil treatment showed an EC50 of
718 (1) mM (fig 2C, D). Thus, CF15 cells were less sensitive
to the effect of sildenafil, requiring a higher concentration
than native cells from CF patients to restore function.
The effects of a range of Cl2 channel blockers on the
forskolin/genistein stimulated iodide efflux of sildenafil
treated cells (1 mM for 2 hours at 37 C˚) was determined.
The efflux was inhibited by glibenclamide and DPC but
not by DIDS or calixarene, demonstrating that sildenafil
had recruited functional DF508-CFTR Cl2 channels at the
apical membrane. The results indicate that, like MPB-91,
sildenafil was able to restore the chloride channel
activity of DF508-CFTR at 37 C˚. Immunolocalisation of
DF508-CFTR in CF15 cells indicated that, following treat-
ment for 2 hours at 37 C˚ with 1 mM sildenafil, DF508-CFTR
had moved from within the cell to an apical location (data
not shown).
DISCUSSION
This study has shown, for the first time, a dramatic and rapid
effect of the PDE5 inhibitor sildenafil in directing DF508-
CFTR to the apical membrane in native CF airway cells from
patients with CF. The effect is comparable to our previously
demonstrated effect of MPB compounds.8 By comparison,
other non-selective treatments such as low temperature (25–
27 C˚), glycerol, or 4-phenylbutyrate have required long term
exposure to show modest effects on DF508-CFTR traffick-
ing.14 The technique that we have developed for confocal
immunofluorescence localisation of wild type and DF508-
CFTR in native nasal epithelial cells from control and CF
individuals allows CFTR location to be visualised in indivi-
dual cells, the pattern of mislocalisation quantified, and the
actions of pharmacological agents on DF508-CFTR trafficking
evaluated. In agreement with our previous studies8 and those
of others,7 9 DF508-CFTR was predominantly mislocalised
and present within the cell. DF508-CFTR was detectable at
the apical membrane in a minority (approximately 10%) of
cells.
The present studies have also identified a new CFTR
trafficking mutation in NBD2 (R1283M) that has not
previously been investigated. The only other report of altered
trafficking of CFTR with a mutation in NBD2 is N1303K.15
The present results, showing that sildenafil corrects DF508-
and R1283M-CFTR location, both mutations in nucleotide
binding domains, will provide insights into the mechanism of
action of drugs that increase CFTR trafficking. It is
noteworthy that neither sildenafil nor MPB compounds
affect the trafficking of wild type CFTR, nor of other normal
ER or Golgi proteins, thus providing a selective action. We
have previously provided evidence16 that the speed and
selectivity of the effect of MPB compounds on DF508-CFTR
trafficking is due to direct binding to the CFTR protein at a
site within the first cytoplasmic domain. It is therefore
possible that sildenafil also binds directly to DF508-CFTR,
although an action through cyclic GMP signalling has not
been ruled out.
There is agreement that DF508-CFTR has substantial Cl2
channel activity when present at the apical membrane,
which some studies suggest is comparable to that of wild-
type CFTR.1 Thus, the present study showing recruitment
of DF508-CFTR to the apical membrane in native CF cells
in response to the drug sildenafil, is a major step forward
in restoring CFTR function. Although the concentration
of sildenafil shown to traffic DF508-CFTR in a CF cell
line was higher than in native cells, sensitivities may
vary between cell lines, isolated native cells, and in vivo,
and this will form the basis of future studies. Nevertheless,
the finding that sildenafil, a relatively safe drug already
in clinical use, has a dramatic effect in increasing DF508-
CFTR trafficking will assist in the discovery of new
derivatives and is a major advance towards developing a
rational drug treatment aimed at repair or rescue of activity
of the mutant CF gene protein. The present results indicate
that an approach to drug therapy using CFTR trafficking
drugs is likely to be applicable to the majority of patients with
CF.
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